What does Mounjaro mean, and what does the name tell you?

Why brand names and drug names are two different things

When a medicine reaches the market, it carries two names. The international non-proprietary name (tirzepatide) is assigned by the World Health Organization and tells prescribers and pharmacists exactly which molecule they are dealing with. The brand name, Mounjaro, belongs to Eli Lilly and was chosen to be memorable and distinctive rather than descriptive. This is standard pharmaceutical practice: paracetamol is the drug; Panadol is one brand. Understanding that split matters because pharmacists, NHS guidance, and NICE appraisals will often refer to tirzepatide rather than Mounjaro, and both names point to the same medicine.

A common misconception is that a brand name carries some signal about strength, class or purpose. It does not. You can read more about the molecule itself on the tirzepatide overview page, which goes into the pharmacology in more detail. What matters clinically is the INN, and tirzepatide's INN is unusually informative once you know what to look for.

What tirzepatide actually means (and why it matters more than Mounjaro)

The name tirzepatide follows a convention used for medicines in this class. The suffix -tide indicates a peptide, a short chain of amino acids that mimics a naturally occurring hormone in the body. The prefix encodes the manufacturer's designation for the molecule. It is the mechanism, though, that sets tirzepatide apart: it activates both the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1), slowing gastric emptying and reducing appetite through two distinct pathways simultaneously. No other weight-management medicine licensed in the UK does this. NICE's appraisal of tirzepatide, published in December 2024, described the evidence base as supporting meaningful average weight loss in adults with obesity, the NICE technology appraisal TA1026 sets out the full clinical picture.

If you have seen the name Zepbound and wondered whether it is related, it is: Zepbound is the US brand name for tirzepatide, sold in America by Eli Lilly under a different label. It is not a UK product and is not available from UK pharmacies. In the UK, tirzepatide is Mounjaro, full stop. The Mounjaro page on our site covers the UK licence, dosing schedule and eligibility criteria in full.

Does the meaning of the name change anything about whether it suits you?

Honestly, no. The name is marketing; the decision is clinical. What a prescriber weighs up is your BMI, your weight-related health conditions, your medication history, and any contraindications. Under the UK licence, tirzepatide is approved for adults with a BMI of 30 or above, or 27 and above where a weight-related condition such as high blood pressure, dyslipidaemia or type 2 diabetes is present. Lower thresholds can apply for some ethnic backgrounds under UK guidance. None of that is encoded in the word Mounjaro.

Cost is often part of the decision too. Since Eli Lilly revised list pricing in September 2025, private treatment has typically ranged from around £149 to £375 per month depending on dose and provider, a range explored in more detail on the Mounjaro cost page. The name you see on the pen makes no difference to whether the treatment is right for you; that is what a clinical review is for.

What changes as treatment progresses, and where the name stops being relevant

Once treatment is underway, patients and prescribers tend to refer to the medicine by its dose rather than its name. The starting dose, 2.5mg, is there to let your system adjust before titrating upward, typically in four-week steps. Questions about how long Mounjaro is intended to be used often arise at this stage, as do questions about what happens when treatment ends, something covered on the weaning-off Mounjaro page. The NHS medicines page for tirzepatide on the NHS website is the clearest patient-level resource on side effects and storage, and is worth bookmarking alongside the Patient Information Leaflet that comes in the box.

Some people also ask about approaches like microdosing Mounjaro, another case where the terminology can obscure more than it reveals, and where a prescriber's view is essential before making any changes to a licensed regimen. The name on the pen matters far less than the clinical relationship behind it. If you would like to understand whether tirzepatide could be appropriate for your situation, our prescribers are the right starting point. Speak to our prescribers through a free consultation reviewed the same working day.